Business Context and Reporting Period
Company: Dr. Reddy's Laboratories Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Second Quarter (Q2) of Fiscal Year 2012, ended September 30, 2011.
Context: The filing includes unaudited consolidated financial results under IFRS and press releases regarding the launch of generic Zyprexa in the United States.
Key Financial Metrics
| Metric | Q2 FY12 (INR Billion) | Q2 FY12 (USD Million) | Q2 FY11 (INR Billion) | Q2 FY11 (USD Million) | YoY Growth |
|---|---|---|---|---|---|
| Revenue | 22.7 | 462 | 18.7 | 381 | 21% |
| Gross Profit | 12.2 | 249 | 10.0 | 204 | 22% |
| Gross Margin | 54% | - | 53% | - | +100 bps |
| Adjusted EBITDA | 5.1 | 104 | 4.2 | 87 | 20% |
| Adjusted EBITDA Margin | 23% | - | 23% | - | Flat |
| Adjusted Profit After Tax (PAT) | 3.1 | 63 | 2.9 | 58 | 8% |
| Adjusted PAT Margin | 14% | - | 15% | - | -100 bps |
| Diluted EPS | 18.1 INR | $0.40 | 16.9 INR | $0.30 | 7% |
Liquidity and Balance Sheet (as of Sept 30, 2011):
- Cash and Cash Equivalents: INR 7,596 million ($155 million).
- Total Loans and Borrowings: INR 31,303 million ($638 million).
- Capital Expenditure (H1 FY12): INR 3.6 billion ($73 million).
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenue grew 21% year-over-year, driven by an 18% increase in Global Generics and a 28% increase in Pharmaceutical Services and Active Ingredients (PSAI).
- North America Performance: Global Generics revenue in North America surged 45% in USD terms, led by new product launches and market share gains.
- Europe Decline: Global Generics revenue in Europe declined 10%, primarily due to a 27% drop in Germany caused by tender impacts.
- Cost Structure: Selling, General & Administrative (SG&A) expenses rose 26% due to higher freight costs, inflation, manpower increments, and incremental costs at US manufacturing facilities (Bristol and Shreveport).
- Finance Costs: Net finance costs increased due to higher net interest expense, partially offset by a net forex gain of INR 151 million compared to a loss in the prior year.
Guidance, Outlook, and Material Events
- Product Launches: The company launched 28 new generic products in the quarter. Notably, it announced the commercial launch of generic Olanzapine (Zyprexa) in the US in partnership with Teva, securing 180 days of marketing exclusivity for the 20 mg tablet.
- Regulatory Filings: Filed 17 new product registrations and 11 Drug Master Files (DMFs) globally. Cumulative ANDA filings stand at 177, with 76 pending USFDA approval (40 Paragraph IV, 11 First-to-File).
- Market Position: 24 prescription products in the North American portfolio rank in the Top 3 for market share. In Russia, the company holds a 12th rank in market share with 20% secondary prescription sales growth.
- Unusual Items: Adjusted EBITDA and PAT figures include a benefit from a partial reversal of a Voluntary Retirement Scheme (VRS) provision booked in Q1. Adjusted PAT also includes interest on bonus debentures.
Investor Verification Checklist
- North America Growth Sustainability: Verify the pipeline of new product launches sustaining the 45% USD growth in North America.
- Europe Recovery: Assess the timeline for recovery in the German market following tender-related revenue declines.
- Zyprexa Commercialization: Monitor the revenue contribution from the generic Zyprexa launch and the expiration of the 180-day exclusivity period.
- Cost Inflation: Track the impact of rising freight costs and inflation on SG&A expenses and future margins.
- Debt Levels: Review the trajectory of total loans and borrowings, which increased to INR 31.3 billion.